The Philippines Has Approved ReCOV For Phase II/III Cinical Trial
Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial ReCOV induced high levels of neutralizing antibodies against SARS-CoV-2 and Variants of Concern such as Omicron and Delta Rhecogen , a subsidiary focused on mRNA vaccines of the infectious diseases, launched the world's first lyophilized...
The Friso #ReallyKnowPoop Constipation Survey: How common is constipation for the Singaporean Toddler?
SINGAPORE, Jan. 17, 2022 /PRNewswire/ -- Key survey findings Constipation is a common problem among toddlers in Singapore, with parents indicating that their child experienced constipation 'every few days' or 'every few weeks' 9 in 10 parents indicated they were 'confident' or 'very confident' in identifying toddler constipation, however; Parents surveyed said they...
Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate’s Global Phase II Clinical Trial in Treating Parkinson’s Disease
SHANGHAI, Jan. 17, 2022 /PRNewswire/ -- On January 13, 2022, Green Valley (Shanghai) Pharmaceuticals Co., Ltd. received the letter from the US Food and Drug Administration (FDA) on the Investigational New Drug (IND) application for the global multi-center phase-II clinical trial of Oligomannate (marketed as "GV-971"), the company's innovative drug for treating Alzheimer's disease (AD). The letter indicated the "Study...
MicroPort CRM Receives Approval in Japan for Alizea Bluetooth Pacemaker
CLAMART, France, Jan. 17, 2022 /PRNewswire/ -- MicroPort CRM, a pioneering company in the field of Cardiac Rhythm Management, headquartered in France, recently received PMDA Japanese regulation agency approval for its latest range of implantable pacemakers, Alizea. The devices are equipped with Bluetooth technology for streamlined remote monitoring when paired with MicroPort CRM's SmartView Connect home monitor, already approved in...
Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA
BEIJING and SHANGHAI and BOSTON, Jan. 17, 2022 /PRNewswire/ -- Jacobio's self-developed global first-in-class drug Aurora A inhibitor JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US. Jacobio plans to initiate a Phase I/IIa clinical trial in patients with advanced solid tumors in the US. JAB-2485...
CStone announces the clinical data from registrational study of Sugemalimab in stage III non-small cell lung cancer published in The Lancet Oncology
SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the registrational clinical data from sugemalimab (the GEMSTONE-301 study) in stage III non-small cell lung cancer (NSCLC) were published in the world-leading clinical oncology journal, The Lancet...
CStone announces the registrational clinical study results of sugemalimab in stage IV non-small cell lung cancer published in The Lancet Oncology
SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that results of the GEMSTONE-302 study, a randomized double-blind registrational clinical study for sugemalimab as the first-line treatment of stage IV non-small cell lung cancer (NSCLC) were published...
French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge City
GUANGZHOU, ChinaJan. 15, 2022 /PRNewswire/ -- On the afternoon of January 14th, Mr. Sylvain FOURRIERE, Consul General of France in Guangzhou, and officers from consulates general of 9 countries including Britain, Canada and Switzerland visited China-Singapore Guangzhou Knowledge City and Singapore-based Biosyngen Pte. Ltd. ("Biosyngen"). Government representatives from Guangzhou Foreign Affairs Office, Huangpu District, Guangzhou...
China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin
TAIZHOU, China, Jan. 14, 2022 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that it develops and commercializes the Kuihuapan After-Soaking-Oral TCMP...
I-Mab Announces Execution of Senior Management Team Share Purchase Plan
The execution demonstrates senior management team's tremendous confidence in the Company's innovative globally competitive pipeline and long-term growth prospects SHANGHAI and GAITHERSBURG, MD., Jan. 14, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that...
